Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Perspective Therapeutics Inc. (CATX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/24/2026: CATX (3-star) is a STRONG-BUY. BUY since 36 days. Simulated Profits (94.27%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.33
1 Year Target Price $13.33
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 637.92M USD | Price to earnings Ratio - | 1Y Target Price 13.33 |
Price to earnings Ratio - | 1Y Target Price 13.33 | ||
Volume (30-day avg) 14 | Beta 1.79 | 52 Weeks Range 1.60 - 6.16 | Updated Date 02/24/2026 |
52 Weeks Range 1.60 - 6.16 | Updated Date 02/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -13330.62% |
Management Effectiveness
Return on Assets (TTM) -17.24% | Return on Equity (TTM) -37.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 71168835 | Price to Sales(TTM) 593.41 |
Enterprise Value 71168835 | Price to Sales(TTM) 593.41 | ||
Enterprise Value to Revenue 68.73 | Enterprise Value to EBITDA -21.91 | Shares Outstanding 113914078 | Shares Floating 52374831 |
Shares Outstanding 113914078 | Shares Floating 52374831 | ||
Percent Insiders 10.79 | Percent Institutions 52.03 |
Upturn AI SWOT
Perspective Therapeutics Inc.
Company Overview
History and Background
Perspective Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel targeted radiotherapeutic and diagnostic agents. Founded in 2017, its primary focus has been on building a pipeline of therapies for cancer and other serious diseases. A significant milestone was the acquisition by POINT Biopharma in 2023, which aimed to accelerate the development and commercialization of Perspective's radioligand therapy portfolio.
Core Business Areas
- Radioligand Therapies: Development of targeted radiopharmaceuticals designed to deliver therapeutic radiation directly to cancer cells, minimizing damage to healthy tissues. This includes both therapeutic and diagnostic applications.
- Diagnostic Imaging Agents: Creation of agents that can be used in conjunction with imaging technologies (like PET scans) to detect and characterize tumors, aiding in diagnosis and treatment planning.
Leadership and Structure
Following the acquisition by POINT Biopharma, the leadership and structure are now integrated within POINT Biopharma. Key leadership roles would typically include a CEO, CSO, CFO, and heads of various R&D, clinical, and commercial operations.
Top Products and Market Share
Key Offerings
- Product Name 1: No specific product names are publicly disclosed as being in late-stage development or on the market under the Perspective Therapeutics Inc. name prior to its acquisition. Their focus was on building a pipeline of early to mid-stage investigational radioligand therapies.
Market Dynamics
Industry Overview
The radiopharmaceutical market is a rapidly growing segment within the broader oncology and diagnostics industries. It is characterized by significant scientific innovation, high development costs, and increasing interest from both pharmaceutical giants and smaller biotech firms due to the potential for highly targeted and personalized treatments.
Positioning
Prior to its acquisition, Perspective Therapeutics Inc. was positioned as an emerging player in the radioligand therapy space, focusing on proprietary targeting ligands and radioisotope combinations. Its competitive advantage lay in its scientific approach to developing novel agents.
Total Addressable Market (TAM)
The global radiopharmaceutical market is projected to grow substantially, with estimates varying but generally expected to reach tens of billions of USD in the coming years. Perspective Therapeutics Inc.'s (now POINT Biopharma's) position within this TAM is focused on specific cancer indications where radioligand therapies can offer a significant improvement over existing treatments.
Upturn SWOT Analysis
Strengths
- Proprietary targeting ligand technology.
- Focus on a rapidly growing and innovative therapeutic area (radioligand therapy).
- Acquisition by a larger, well-capitalized company (POINT Biopharma) provides enhanced resources.
Weaknesses
- Historically, as a smaller entity, limited resources for large-scale clinical trials and commercialization.
- Long development timelines typical of biopharmaceutical products.
- Dependence on successful clinical trial outcomes.
Opportunities
- Expanding indications for existing and pipeline radioligand therapies.
- Leveraging POINT Biopharma's existing infrastructure and expertise for accelerated development and commercialization.
- Partnerships and collaborations with larger pharmaceutical companies.
- Increasing adoption of precision medicine.
Threats
- Competition from other radiopharmaceutical developers and conventional cancer therapies.
- Regulatory hurdles and lengthy approval processes.
- Challenges in manufacturing and supply chain for radiopharmaceuticals.
- Potential for unexpected clinical trial failures.
Competitors and Market Share
Key Competitors
- Novartis (NVS)
- Telix Pharmaceuticals (TLX)
- Lantheus Holdings (LNTH)
- Bayer AG (BAYN)
Competitive Landscape
Perspective Therapeutics Inc., now integrated into POINT Biopharma, faces intense competition from established pharmaceutical companies with significant R&D budgets and existing market presence, as well as other specialized radiopharmaceutical firms. Their advantages lie in targeted therapies, while challenges include the high cost of development and market penetration.
Major Acquisitions
POINT Biopharma
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: To accelerate the development and commercialization of Perspective's radioligand therapy pipeline and integrate it with POINT Biopharma's existing radiopharmaceutical assets and expertise.
Growth Trajectory and Initiatives
Historical Growth: Historically, Perspective Therapeutics Inc.'s 'growth' was defined by scientific advancements, pipeline progression, and securing funding. The acquisition by POINT Biopharma represents a significant shift in its growth trajectory.
Future Projections: Future projections for the combined entity would be part of POINT Biopharma's investor relations and analyst reports. These would focus on the potential success of their combined radioligand therapy pipeline.
Recent Initiatives: The most significant recent initiative was its acquisition by POINT Biopharma. The combined entity is likely focused on advancing clinical trials for its radioligand candidates.
Summary
Perspective Therapeutics Inc., now part of POINT Biopharma, is positioned within the dynamic radiopharmaceutical market. Its strengths lie in its innovative radioligand technology, amplified by the resources of its acquirer. However, it faces significant competition and the inherent risks of drug development. Continued success hinges on successful clinical trials and effective market penetration for its advanced pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases (historical for Perspective Therapeutics Inc., current for POINT Biopharma).
- Industry market research reports.
- Financial news outlets.
- Publicly available SEC filings for POINT Biopharma.
Disclaimers:
This analysis is based on publicly available information and may not reflect all current or future developments. Financial data and market share figures are estimates and subject to change. The acquisition by POINT Biopharma significantly alters the standalone profile of Perspective Therapeutics Inc.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Perspective Therapeutics Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2005-11-10 | CEO & Director Mr. Johan M. Spoor | ||
Sector Healthcare | Industry Medical Devices | Full time employees 138 | |
Full time employees 138 | |||
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha; and PSV4XX, a differentiated prostate-specific membrane antigen-targeted alpha therapy. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.